November 2023 : Eli Lilly received US FDA approval for ZEPBOUND, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors
The STEP 9 trial found that semaglutide reduced both body weight and knee osteoarthritis pain compared to placebo [24], and a large observational study using data from the Shanghai Osteoarthritis Cohort found that people on GLP-1 receptor agonists had a significantly lower rate of knee surgery, 1.7 percent compared to 5.9 percent in the non-GLP-1 group, with weight loss accounting for about 32 percent of that protective effect [22]
This injection is often used as an adjunct therapy in various conditions where oxidative stress is a concern
Injection site reactions Mild redness, swelling, or itching at the injection site
Grabrucker S, Marizzoni M, Silajdi E, Lopizzo N, Mombelli E, Nicolas S, et al
S5E, left panel), a time-point at which mice presented a significant increase in EE (in both light and dark phases) (Fig
